Sysmex Corporation (SSMXY)
| Market Cap | 5.23B -54.8% |
| Revenue (ttm) | 3.21B +0.2% |
| Net Income | 285.40M -22.6% |
| EPS | 0.46 -22.5% |
| Shares Out | n/a |
| PE Ratio | 18.34 |
| Forward PE | n/a |
| Dividend | 0.25 (3.02%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 14,133 |
| Average Volume | 213,208 |
| Open | 8.25 |
| Previous Close | 8.39 |
| Day's Range | 8.17 - 8.25 |
| 52-Week Range | 8.15 - 18.49 |
| Beta | 0.65 |
| RSI | 41.35 |
| Earnings Date | May 14, 2026 |
About Sysmex
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers non-clinical blood testing and cell analysis for hematology, such as XN-V series, a software for laboratory animal corresponding to XN series fully automated hematology analyzers; XN-Series, a fully automated flagship hematology analyzers; and Automated hematology analyzer ProCyte Dx for Research applications, a housed in a compact body that simultaneously measures five types of leukocytes and reticulocyte co... [Read more]
Financial Performance
In fiscal year 2025, Sysmex's revenue was 508.64 billion, an increase of 10.21% compared to the previous year's 461.51 billion. Earnings were 53.67 billion, an increase of 8.12%.
Financial numbers in JPY Financial StatementsNews
Sysmex Earnings Call Transcript: Q2 2026
First half results saw declines in revenue and profit due to Japan's ecosystem transition, inventory devaluation, and a challenging Chinese market, while overseas regions excluding China performed well. Full-year forecasts were revised down, but growth is expected in emerging markets and new business areas.
Sysmex upgraded to Buy from Hold at Jefferies
Jefferies analyst Stephen Barker upgraded Sysmex to Buy from Hold with a price target of 3,100 yen, up from 2,700 yen. The company’s China outlook stabilizing and India is “taking…